myTomorrows raises €25M in patient access funding round

Europe’s healthcare technology sector continues its momentum with patient access platforms emerging as a critical bridge between pharmaceutical innovation and real-world medical need. As regulatory frameworks evolve and drug approval timelines remain lengthy, companies facilitating early access to treatments are attracting significant investor attention across European markets.

myTomorrows, the Amsterdam-based patient access platform, has secured €25 million in growth equity financing to expand its mission of connecting patients with investigational treatments. The funding round was led by Avego, with participation from existing investors, marking a significant milestone in European digital health investment activity.

Patient access funding attracts European growth investors

The investment from Avego reflects growing institutional confidence in the patient access sector, particularly within Europe’s increasingly sophisticated healthcare technology ecosystem. Unlike traditional pharma services companies, myTomorrows operates at the intersection of regulatory expertise and digital infrastructure, positioning itself as essential infrastructure for pharmaceutical companies navigating complex global access requirements.

“Patient access represents one of healthcare’s most pressing challenges, with millions waiting for approved therapies while promising treatments remain trapped in development pipelines,” noted the lead investor. The timing aligns with heightened regulatory focus on expanded access programmes across European Union markets, where national health systems are increasingly supportive of structured early access initiatives.

The investor composition suggests confidence in myTomorrows’ European market positioning, with growth equity backing indicating the platform has achieved meaningful scale metrics. For Avego, this represents a strategic bet on healthcare infrastructure plays that benefit from regulatory tailwinds rather than fighting against compliance complexity.

Global expansion strategy leverages European regulatory expertise

myTomorrows’ approach differentiates itself by combining pharmaceutical industry expertise with patient-centric technology, creating what founder and CEO Michel van Houten describes as “a bridge between innovation and access that works within existing regulatory frameworks rather than attempting to disrupt them.” This positioning proves particularly valuable in European markets, where medical device regulations and pharmaceutical oversight require nuanced navigation.

The €25 million injection will fuel international expansion, with particular emphasis on strengthening operations across key European healthcare markets including Germany, France, and the United Kingdom. Unlike many healthcare technology companies that struggle with fragmented European compliance requirements, myTomorrows benefits from regulatory complexity, as pharmaceutical companies increasingly seek specialised partners for multi-jurisdiction access programmes.

“We’re seeing unprecedented demand from both pharmaceutical partners and healthcare providers for structured patient access solutions,” van Houten explained. “European regulatory frameworks are evolving to support earlier patient access, creating a significant opportunity for platforms that can navigate these systems effectively.”

The funding positions myTomorrows advantageously against competitors in the patient access space, many of which remain focused on single-market solutions or lack the regulatory expertise required for complex multi-national programmes. With European pharmaceutical companies increasingly prioritising patient access as a competitive differentiator, specialised platforms like myTomorrows are becoming essential infrastructure rather than optional services.

This funding round signals broader institutional recognition of patient access as a critical healthcare infrastructure layer, with European investors demonstrating appetite for companies that solve regulatory complexity rather than attempt to circumvent it. For myTomorrows, the capital provides runway to capture growing demand while European healthcare systems increasingly embrace structured early access programmes.